NCT07085650 The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation
| NCT ID | NCT07085650 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Hospital of China Medical University |
| Condition | Atrial Fibrillation (AF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-12-30 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic and can lead to valve regurgitation and a poor prognosis. At present, atrial fibrillation ablation is one of the most effective means for the recurrence of atrial fibrillation in clinical practice, but the recurrence rate is high. Therefore, it is of great significance to find the predictors of relapse after atrial fibrillation ablation for clinical precision treatment. three-dimensional transesophageal ultrasound (3D-TEE) can comprehensively evaluate the valve regurgitation, flap ring changes, atrial or auricular thrombosis in patients with atrial fibrillation. It is also a necessary examination before atrial fibrillation ablation. Therefore, this study intends to combine 3D-TEE and three-dimensional transthoracic echocardiographic (3D-TTE) examination to evaluate the cardiac structure and function of patients. To comprehensively evaluate atrial fibrillation valve regurgitation and explore the predictors of recurrence after atrial fibrillation ablation.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years old; 2. Patients who came to the hospital with atrial fibrillation and intended to undergo ablation. Exclusion Criteria: 1. \- History of left atrial or left atrial appendix thrombus, new cerebral infarction and myocardial infarction (\< 6 months); 2. Congenital heart disease, valvular heart disease, dilated heart disease, hypertrophic cardiomyopathy, pacemaker implantation, artificial valve replacement; 3. hyperthyroidism, severe liver and kidney insufficiency; 4. Proposed cardiac pacemaker implantation; 5. Previous history of catheter ablation; 6. The quality of three-dimensional transesophageal images was insufficient and could not be analyzed; 7. refuse to sign the informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07085650 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07085650 currently recruiting?
Yes, NCT07085650 is actively recruiting participants. Contact the research team at cmu1h_mcy@126.com for enrollment information.
Where is the NCT07085650 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT07085650 clinical trial?
NCT07085650 is sponsored by First Hospital of China Medical University. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.